Il y a eu 50 transactions d'initiés récentes enregistrées pour Xilio Therapeutics, Inc. (XLO), dont 36 achats et 11 ventes. Le total des achats d'initiés s'élève à $14.86M et le total des ventes d'initiés à $12.1M.
Les initiés notables ayant une activité récente comprennent Shannon James Samuel, Gilead Sciences, Inc., Brennan Kevin M.. Les transactions d'initiés peuvent fournir des indications sur la façon dont la direction perçoit la valorisation et les perspectives futures de l'action.
Transactions d'Initiés — XLO
| Date |
Nom |
Rôle |
Type de Transaction |
Actions |
Prix Moyen |
Valeur |
Actions détenues |
| 2026-03-26 |
Shannon James Samuel |
Director |
Achat Informatif |
5,000 |
$8.79 |
$43.95K |
10,000 |
| 2026-02-13 |
Gilead Sciences, Inc. |
10 Percent Owner |
Achat Informatif |
3,739,000 |
$0.00 |
$373.90 |
40,384,266 |
| 2026-01-02 |
Brennan Kevin M. |
SVP, Finance and Accounting |
Vente Informative |
1,826 |
$0.64 |
$1.17K |
6,371 |
| 2026-01-02 |
Frankenfield Christopher James |
Chief Financial Officer |
Vente Informative |
7,030 |
$0.64 |
$4.52K |
24,766 |
| 2026-01-01 |
Russo Rene |
President and CEO |
Exercice d'Options (Vente) |
44,250 |
- |
- |
88,500 |
| 2026-01-01 |
Brennan Kevin M. |
SVP, Finance and Accounting |
Exercice d'Options |
5,000 |
- |
- |
8,197 |
| 2026-01-01 |
Frankenfield Christopher James |
Chief Financial Officer |
Exercice d'Options |
19,375 |
- |
- |
31,796 |
| 2026-01-01 |
Luptakova Katarina |
Chief Medical Officer |
Exercice d'Options |
16,625 |
- |
- |
33,250 |
| 2025-12-31 |
Russo Rene |
President and CEO |
Attribution de RSU |
1,500,258 |
$0.84 |
$1.26M |
1,500,258 |
| 2025-12-31 |
Brennan Kevin M. |
SVP, Finance and Accounting |
Attribution de RSU |
95,221 |
$0.84 |
$80.08K |
95,221 |
| 2025-12-31 |
Frankenfield Christopher James |
Chief Financial Officer |
Attribution de RSU |
668,789 |
$0.84 |
$562.45K |
668,789 |
| 2025-12-31 |
Luptakova Katarina |
Chief Medical Officer |
Attribution de RSU |
451,885 |
$0.84 |
$380.04K |
451,885 |
| 2025-11-26 |
Gilead Sciences, Inc. |
10 Percent Owner |
Exercice d'Options (ITM) |
13,335,000 |
$0.75 |
$10M |
- |
| 2025-11-21 |
Russo Rene |
President and CEO |
Restitution d'Actions |
135,134 |
$11.69 |
$1.58M |
- |
| 2025-11-21 |
Brennan Kevin M. |
SVP, Finance and Accounting |
Restitution d'Actions |
20,000 |
$1.08 |
$21.6K |
- |
| 2025-11-21 |
Frankenfield Christopher James |
Chief Financial Officer |
Restitution d'Actions |
150,000 |
$2.75 |
$412.5K |
- |
| 2025-11-21 |
Luptakova Katarina |
Chief Medical Officer |
Restitution d'Actions |
25,000 |
$2.79 |
$69.63K |
- |
| 2025-06-17 |
Shannon James Samuel |
Director |
Achat Informatif |
25,000 |
$0.69 |
$17.22K |
70,000 |
| 2025-06-16 |
Shannon James Samuel |
Director |
Achat Informatif |
45,000 |
$0.69 |
$30.87K |
45,000 |
| 2025-06-16 |
Russo Rene |
President and CEO |
Achat Informatif |
36,289 |
$0.68 |
$24.68K |
281,172 |
| 2025-06-11 |
Clancy Paul J |
Director |
Attribution de RSU |
31,000 |
$0.69 |
$21.48K |
31,000 |
| 2025-06-11 |
Shannon James Samuel |
Director |
Attribution de RSU |
31,000 |
$0.69 |
$21.48K |
31,000 |
| 2025-06-11 |
Bonstein Sara |
Director |
Attribution de RSU |
31,000 |
$0.69 |
$21.48K |
31,000 |
| 2025-06-11 |
Brennan Aoife |
Director |
Attribution de RSU |
31,000 |
$0.69 |
$21.48K |
31,000 |
| 2025-06-11 |
Ross Robert W. |
Director |
Attribution de RSU |
31,000 |
$0.69 |
$21.48K |
31,000 |
| 2025-06-11 |
Rossi Christina |
Director |
Attribution de RSU |
31,000 |
$0.69 |
$21.48K |
31,000 |
| 2025-06-11 |
Xu Yuan |
Director |
Attribution de RSU |
31,000 |
$0.69 |
$21.48K |
31,000 |
| 2025-06-11 |
Curran Daniel J. |
Director |
Attribution de RSU |
31,000 |
$0.69 |
$21.48K |
31,000 |
| 2025-06-10 |
Bello Akintunde Olatokumbo |
Officer |
Inconnu |
- |
- |
- |
- |
| 2025-06-10 |
Bello Akintunde Olatokumbo |
Director |
Attribution de RSU |
62,000 |
$0.70 |
$43.4K |
62,000 |
| 2025-06-05 |
Gilead Sciences, Inc. |
10 Percent Owner |
Achat Informatif |
13,335,000 |
$0.75 |
$10M |
13,335,000 |
| 2025-04-15 |
Russo Rene |
President and CEO |
Attribution de RSU |
190,000 |
$0.71 |
$135.28K |
190,000 |
| 2025-04-15 |
Frankenfield Christopher James |
Chief Financial Officer |
Attribution de RSU |
75,000 |
$0.71 |
$53.4K |
75,000 |
| 2025-01-02 |
Brennan Kevin M. |
SVP, Finance and Accounting |
Vente Informative |
1,803 |
$0.98 |
$1.77K |
3,197 |
| 2025-01-02 |
Frankenfield Christopher James |
Chief Financial Officer |
Vente Informative |
6,954 |
$0.98 |
$6.84K |
12,421 |
| 2025-01-01 |
Russo Rene |
President and CEO |
Exercice d'Options (Vente) |
44,250 |
- |
- |
132,750 |
| 2025-01-01 |
Brennan Kevin M. |
SVP, Finance and Accounting |
Exercice d'Options |
5,000 |
- |
- |
5,000 |
| 2025-01-01 |
Frankenfield Christopher James |
Chief Financial Officer |
Exercice d'Options |
19,375 |
- |
- |
19,375 |
| 2025-01-01 |
Luptakova Katarina |
Chief Medical Officer |
Exercice d'Options |
16,625 |
- |
- |
16,625 |
| 2025-01-01 |
Russo Rene |
Officer |
Inconnu |
- |
- |
- |
- |
| 2024-12-18 |
Gilead Sciences, Inc. |
10 Percent Owner |
Achat Informatif |
1,759,978 |
$1.04 |
$1.83M |
9,105,451 |
| 2024-10-01 |
Brennan Kevin M. |
SVP, Finance and Accounting |
Attribution de RSU |
26,000 |
$0.75 |
$19.5K |
26,000 |
| 2024-08-03 |
Frankenfield Christopher James |
Chief Operating Officer |
Attribution de RSU |
52,000 |
$0.90 |
$46.54K |
52,000 |
| 2024-06-14 |
Clancy Paul J |
Director |
Attribution de RSU |
25,000 |
$1.02 |
$25.5K |
25,000 |
| 2024-06-14 |
Bonstein Sara |
Director |
Attribution de RSU |
25,000 |
$1.02 |
$25.5K |
25,000 |
| 2024-06-14 |
Ross Robert W. |
Director |
Attribution de RSU |
25,000 |
$1.02 |
$25.5K |
25,000 |
| 2024-06-14 |
Rossi Christina |
Director |
Attribution de RSU |
25,000 |
$1.02 |
$25.5K |
25,000 |
| 2024-06-14 |
Xu Yuan |
Director |
Attribution de RSU |
25,000 |
$1.02 |
$25.5K |
25,000 |
| 2024-06-14 |
Curran Daniel J. |
Director |
Attribution de RSU |
25,000 |
$1.02 |
$25.5K |
25,000 |
| 2024-06-13 |
Shannon James Samuel |
Officer |
Inconnu |
- |
- |
- |
- |
■ Informatif — transaction sur marché ouvert (la plus significative)
■ Non informatif (achat) — récompense, exercice d'option, conversion
■ Non informatif (vente) — retenue fiscale, vente à l'acquisition
■ Neutre — don, fiducie, expiration
Les autres consultent aussi
